Skip to contentSkip to main content

Soluble fibre · Evidence and safety guide

Psyllium: benefits, dose, cholesterol effects and safe use

Among evaluated fibre supplements, psyllium had the clearest signal for adult chronic idiopathic constipation, but the AGA/ACG fibre recommendation is conditional and low-certainty.

It can modestly lower LDL cholesterol, non-HDL cholesterol and ApoB and may improve glucose markers in type 2 diabetes. Safe use always requires enough liquid and screening for swallowing, obstruction and medicine-timing risks.1,2,4,11,15

Limited
Updated August 10, 202632 min readHuman evidence first
Pale psyllium husks and seeds swirling through clear water beside oats, pears and beans on a cream and navy background

At a glance

Psyllium

Overall
Conditional, low-certainty for adult chronic constipation; moderate for lipid biomarkers; narrower for glucose and IBS1,2,11,15,19LimitedFinding: benefit supported
Most likely to benefit
Adults with constipation, a low-fibre pattern or a clinician-agreed lipid goal1,2,11ModerateFinding: benefit supported
Constipation range
7–11 g/day in one to three doses in the EMA monograph; labels vary4,6StrongFinding: established use
Lipid-trial dose
About 10.2 g/day in many controlled trials11,12ModerateFinding: benefit supported
Best-supported form
Plain psyllium husk with declared active grams, mixed immediately with the full liquid volume4,5,6,11ModerateFinding: benefit supported
Water
At least 240 mL per labelled dose; never swallow dry4,5,6StrongFinding: established use
Bowel effect
Often 12–72 hours; sometimes two to three days4,6,32StrongFinding: established use
Medicine timing
No universal interval—use the longest medicine, product-label or pharmacist instruction4,5,7StrongFinding: established use
Urgent warning
Chest pain, vomiting, trouble swallowing or breathing, or severe distension after a dose5,6,9StrongFinding: established use

Study findings describe groups, not a guaranteed result for one person.

Research and writing

LongevityMate Editorial Team

Editorial oversight

Lukas Dvorsky, Founder

Clinical review

Not yet assigned or claimed